LSE Leishen ongoing renewable capacity expansions lift core operating outlook for the full fiscal year What Wall Street expects from Kyverna Therapeutics KYTX this quarter KYTX Q4 2025 Kyverna Therapeutics Beats EPS Estimates with Zero Revenue The structural growth drivers for Aon AON Grinds Higher 20260508 Danaos DAC Stock Is It Respecting Levels Q4 2025 EPS Exceeds Expectations